Comment from Aimee Dangalan

My young son has H3 G34 DHG, it is very rare and he has no standard of care or treatments available that are specific to his histone mutation. I would like to ask the FDA to explicitly include rare CNS tumors like Liam's in the guidance and to accept endpoints such as molecular response or durable disease stabilization as sufficient evidence under the framework.